TrialBMJ open2022

Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO.

Job P van Kooten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.